-
公开(公告)号：US20170260200A1
公开(公告)日：2017-09-14
申请号：US15510613
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Paul Andrew BARSANTI , Matthew T. BURGER , Yan LOU , Gisele A. NISHIGUCHI , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Rowland TANNER , Lifeng WAN
IPC: C07D498/08 , A61K31/4418 , A61K31/444 , C07D401/14 , C07D213/74 , C07D405/12 , A61K31/541 , A61K31/5377 , C07D401/04 , C07D405/14 , A61K31/496 , C07D413/14 , C07D451/02 , A61K31/501 , C07D213/85
CPC classification number: C07D498/08 , A61K31/4418 , A61K31/444 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K31/541 , C07D213/74 , C07D213/85 , C07D401/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D411/14 , C07D413/12 , C07D413/14 , C07D451/02
Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20190175606A1
公开(公告)日：2019-06-13
申请号：US16274165
申请日：2019-02-12
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Paul Andrew BARSANTI , Matthew T. BURGER , Michael Patrick DILLON , Alan DIPESA , Cheng HU , Yan LOU , Gisele A. NISHIGUCHI , Yue PAN , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Alice C. RICO , Lina Quattrocchio SETTI , Aaron SMITH , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Roland TANNER , Lifeng WAN , Naeem YUSUFF
IPC: A61K31/5377 , C07D493/10 , C07D403/12 , C07D413/14 , C07D413/12 , C07D403/04 , C07D401/12 , C07D277/42 , C07D239/48 , C07D239/47 , C07D239/42 , C07D237/20 , C07D213/74 , A61K45/06 , A61K31/541 , C07D413/04 , C07D491/08 , C07B59/00 , C07D417/12 , C07D237/24 , C07D491/04 , A61K31/444 , A61K31/501 , C07D513/04 , C07D491/048 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D498/08 , C07D495/04 , C07D493/04 , C07D491/107 , C07D263/58 , C07D487/04 , C07D471/04 , C07D241/20 , C07D405/12 , C07D405/04 , C07D401/04 , C07D233/88 , C07D213/75 , C07D405/14 , C07D401/14
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20180170917A1
公开(公告)日：2018-06-21
申请号：US15510609
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Matthew T. BURGER , Michael Patrick DILLON , Thomas A. DINEEN, Jr. , Yan LOU , Gisele A. NISHIGUCHI , Savithri RAMURTHY , Alice C. RICO , Vivek RAUNIYAR , Martin SENDZIK , Sharadha SUBRAMANIAN , Lina Quattrocchio SETTI , Benjamin R. TAFT , Huw Rowland TANNER , Lifeng WAN
IPC: C07D405/14 , C07D405/12 , C07D305/06 , C07D413/14 , A61P35/00
CPC classification number: C07D405/14 , A61P35/00 , C07D305/06 , C07D405/12 , C07D413/14
Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20170260207A1
公开(公告)日：2017-09-14
申请号：US15601423
申请日：2017-05-22
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Paul Andrew BARSANTI , Matthew T. BURGER , Michael Patrick DILLON , Alan DIPESA , Cheng HU , Yan LOU , Gisele A. NISHIGUCHI , Yue PAN , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Alice C. RICO , Lina Quattrocchio SETTI , Aaron SMITH , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Roland TANNER , Lifeng WAN , Naeem YUSUFF
IPC: C07D513/04 , A61K31/5377 , C07D213/74 , C07D237/22 , C07D213/84 , C07D213/81 , C07D213/75 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D491/08 , A61K31/444 , C07D241/20 , C07D401/04 , C07D237/24 , C07D237/20 , A61K31/501 , C07D239/48 , C07D403/04 , C07D487/04 , C07D471/04 , C07D263/58 , C07D495/04 , C07D491/04 , C07D409/14 , C07D413/04 , C07B59/00 , C07D401/12
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
-
-
Search Results
4
records
(took 0.043 seconds)
